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A systematic review and meta-analysis of
randomized trials of carotid endarterectomy
vs stenting
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Victor M. Montori, MD, MSc,a,c,d and John J. Ricotta, MD,e Rochester, Minn; and Washington, DC
Objective: The purpose of this systematic review and meta-analysis was to synthesize the available evidence derived from
randomized controlled trials (RCTs) regarding the relative efficacy and safety of endarterectomy vs stenting in patients
with carotid artery disease.
Methods: We searched MEDLINE, EMBASE, Current Contents, and Cochrane CENTRAL through July 2010 to update
previous systematic reviews. Two reviewers determined trial eligibility and extracted descriptive, methodologic, and
outcome data (death, nonfatal stroke, and nonfatal myocardial infarction). Random-effects meta-analysis was used to
pool relative risks and the I2 statistic was used to assess heterogeneity.
Results: Thirteen RCTs proved eligible enrolling 7484 patients, of which 80% had symptomatic disease. Methodological
quality was moderate to high, with better quality among RCTs published after 2008. Compared with carotid
endarterectomy, stenting was associated with increased risk of any stroke (relative risk [RR], 1.45; 95% confidence
interval [CI], 1.06-1.99; I2 40%), decreased risk of periprocedural myocardial infarction (MI; RR, 0.43; 95% CI, 0.26-
0.71; I2  0%), and nonsignificant increase in mortality (RR, 1.40; 95% CI, 0.85-2.33; I2  5%). When analysis was
restricted to the two most recent trials with the better methodology and more contemporary technique, we found stenting
to be associated with a significant increase in the risk of any stroke (RR, 1.82; 95% CI, 1.35-2.45) and mortality (RR,
2.53; 95% CI, 1.27-5.08) and a nonsignificant reduction of the risk of MI (RR, 0.39; 95% CI, 0.12-1.23). For every 1000
patients opting for stenting rather than endarterectomy, 19 more patients would have strokes and 10 fewer would have
MIs. Outcome data in asymptomatic patients were sparse and imprecise; hence, these conclusions apply primarily to
symptomatic patients.
Conclusion: Compared with endarterectomy, carotid artery stenting (CAS) significantly increases the risk of any stroke
and decreases the risk of MI. (J Vasc Surg 2011;53:792-7.)
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effective treatment for patients with advanced symptomatic
or asymptomatic carotid disease.1,2 Carotid stenting has
emerged as a less invasive treatment alternative to endarter-
ectomy. Stenting was originally proposed as a safer proce-
dure with lower perioperative morbidity and lower inci-
dence of cranial nerve injury and local complications.3
However, several randomized clinical trials (RCTs) and
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792ubsequent meta-analysis demonstrated possible increased
isk of stroke associated with stenting.4 Conversely, long-
erm follow-up (10 years) of patients randomized to end-
rterectomy showed continued benefit compared to defer-
al of carotid procedures.5
The Society for Vascular Surgery developed clinical
ractice guidelines in 2008 in which they highlighted the
linical dilemma associated with selecting the optimal in-
ervention strategy for carotid bifurcation stenosis.6 Com-
ared to carotid endarterectomy, stenting was associated
ith lower perioperative morbidity, particularly, myocar-
ial infarction (MI), but increased the incidence of stroke.
he carotid committee acknowledged the uncertainty and
mprecise meta-analytic estimates (confidence intervals
CIs] that include both harms and benefits) and issued
elatively weak recommendations based on the literature
vailable at the time. The committee recommended endar-
erectomy and left stenting to be used based on the pa-
ients’ values and preferences (ie, trading a stroke for MI).
However, since 2008, several larger RCTs have been
ublished7,8 and hence, the purpose of this systematic
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Volume 53, Number 3 Murad et al 793review was to update the current literature base and evalu-
ate the relative effects of endarterectomy and stenting on
death, stroke, and MI.
METHODS
Studies that enrolled patients with carotid artery disease
regardless of symptoms and allocated them at random to
either carotid artery endarterectomy or to endovascular
treatment (stenting) were eligible for review. Studies were
included regardless of size or language of publication.
Included studies had to measure the outcomes of interest
(stroke, death, or MI).
A comprehensive literature search of electronic data-
bases (MEDLINE, EMBASE, Web of Science, and Co-
chrane CENTRAL) was conducted from 2008 through
July 2010 using the appropriate terms and text words.
Trials published before 2008 were obtained from our pre-
vious systematic review.4 The details of the search strategy
are available from the authors upon request. Two reviewers,
working independently determined trial eligibility, and ex-
tracted descriptive, methodologic, and outcome data from
each eligible RCT.
Random-effects meta-analysis9 was used to assess rela-
tive risks and the I2 statistic was used to assess heterogeneity
of treatment effect among trials. The I2 statistic represents
the proportion of heterogeneity of treatment effect across
trials that were not attributable to chance or random error.
Hence, a value50% reflects significant heterogeneity that
is due to real differences in study populations, protocols,
interventions, and outcomes.10 The three main patient-
important11 outcomes of interest were death, stroke, and
MI measured at the longest follow-up. We did not use a
composite endpoint of these vascular morbidities because
the results of published trials violated the assumptions of a
common underlying treatment effect needed for proper
Table I. Description of included trials
Trial No. of patients Cerebral protective
Naylor, 199813 23 0
Alberts, 200114 219 0
Brooks, 200115 104 0
CAVATAS, 20013 504 0
Brooks, 200416 85 0
Yadav, 200421 334 96
Mas, 200419 527 92
The SPACE Group, 200620 1200 NR (mixed
Ling, 200618 166 100
Hoffman, 200617 20 NR
Steinbauer et al12 87 0
CREST, 20106 2502 96
ICSS, 20107 1713 72
angio, Angiography; CTA, computed tomography angiography; MRI, mag
All angioplasties were performed with stenting except in Carotid and Verte
aStenosis in symptomatic patients was 50% and in asymptomatic patients w
bStenosis in symptomatic patients was 50% and in asymptomatic patientsinterpretation of composite endpoints (ie, death, MI, and atroke, the components of the composite endpoints re-
ponded to the intervention in different directions).
ntention-to-treat analyses data were extracted whenever
ossible. Absolute effects were estimated using pooled
elative risks and median control event rates from patients
ndergoing carotid endarterectomy in the included trials.
he GRADE framework was used to determine the quality
f evidence.12 Subgroup analyses that were established a
riori and conducted in the original meta-analysis were
epeated (subgroups based on the patients’ symptoms, the
se of protective devices, and stopping trials prematurely).
e excluded two older RCTs in sensitivity analysis in which
he interventions may be deemed less relevant to current
ractice (Carotid and Vertebral Artery Transluminal An-
ioplasty Study [CAVATAS] in which only 26% of patients
eceived stents; and Leicester in which there was no prepro-
edural imaging of the origin of the major head and neck
essels to exclude contraindications to carotid artery stent-
ng (CAS), use of nondedicated stents, and lack of routine
redilation techniques).3,13
ESULTS
The original search identified 10 RCTs.3,13-21 The
pdated search identified 418 potentially eligible refer-
nces; of which only three new RCTs were identified.7,8,22
hus, the total body of evidence included 13 RCTs enroll-
ng 7484 patients; of which 4302 (57%) were participants
f the three new RCTs. One of these three trials is a
ong-term update22 of a previously published preliminary
eport.23 The majority of patients (80%) enrolled in these
3 RCTs was symptomatic. We also identified one publica-
ion describing an individual patient-pooled analysis of
tent-Protected Angioplasty vs Carotid Endarterectomy
SPACE), International Carotid Stenting Study, and End-
es, % Mean age (year) % asymptomatic Degree of stenosis, %
67.2 0 70
68.3 0 60
68.0 0 70
67.0 3 NR
68.2 100 80
72.6 71 50; 80a
69.7 0 60
67.9 0 70
63 Mixed, % unclear 50; 70b
NR 0 70
69 0 70
69 47 50 (angio)
70 (US)
70 (CTA/MRI)
70 0 50
esonance imaging; NR, not reported; US, ultrasound.
rtery Transluminal Angioplasty Study (CAVATAS; only 26%).
80%.
70%.devic
)
netic r
bral Arterectomy vs Angioplasty in Patients with Symptomatic
t
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March 2011794 Murad et alSevere Carotid Stenosis (ie, data sets of the three trials were
merged and analyzed as one trial).24
In general, the overall quality of the body of evidence
(13 RCTs) was high. Although methodological limitations
were noted in the RCTs published before 2008 (allocation
concealment was performed only in 6 of 11 studies, blinded
outcome assessment in 2 of 11, and stopping early before
full recruitment occurred in 5 of 11), the more recent and
larger RCTs7,8 that comprise 56% of all patients included in
this meta-analysis did not have these limitations. Table I
describes the 13 RCTs included in this systematic review
Table I. Continued.
Follow-up (months) Allocation concealment Blin
1 Yes No
12 Probably not Probably
48 Yes No
36 No Outcom
48 Yes No
36 Yes Probably
6 No Outcom
1 Yes No
6 Probably not Probably
45 Yes Probably
64-66 No None
30 Yes Outcom
3 Yes Outcom
Fig. Random-effects meta-analysis comparing carotid a
represent the pooled relative risk (relative risk). Squares an
95% confidence intervals (CIs), respectively.and their methodological quality. 9Meta-analysis. Compared with carotid endarterec-
omy, stenting was associated with increased risk of any
troke (relative risk [RR], 1.45; 95% CI, 1.06-1.99; I2 
0%) and decreased risk of periprocedural MI (RR, 0.43;
5% CI, 0.26- 0.71; I2  0%). The increase in mortality
ssociated with stenting was not statistically significant
RR, 1.40; 95% CI, 0.85-2.33; I2  5%). Results are
epicted in the Fig. Long-term outcomes of stenting (stud-
es with follow-up 12 months) demonstrate similar in-
rease in the risk of any stroke (RR, 1.74; 95% CI, 1.14-
.66) and no significant difference in mortality (RR, 1.02;
Early termination Funding
For harm Mixed
For futility For profit
No Mixed
ssors No Not for profit
No Not for profit
For slow enrollment Mixed
ssors For futility and harm Not for profit
For funding shortage Mixed
No Not for profit
No NR
No For profit
ssors No Mixed (15% for profit)
ssors No Mixed
stenting (CAS) to endarterectomy (CEA). Diamonds
s represent relative risks from individual studies and theirding
not
e asse
not
e asse
not
not
e asse
e assertery
d line5% CI, 0.27-3.86), although the latter results are very
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abling stroke, the effect on stroke was not significant (RR,
1.00; 95% CI, 0.62-1.62). However, this analysis is under-
powered and the result is very imprecise as well.
Absolute treatment effects. Using the median event
rate observed in patients undergoing endarterectomy
across all RCTs as a control event incidence (ie, death
0.86%, MI 1.78%, and stroke 3.91%), we estimated the risk
difference per 1000 patients. Results are summarized in
Table II with the associated quality of evidence.
Subgroup and sensitivity analyses. We found no
significant treatment-subgroup interaction for sub-
groups based on whether the patient had symptoms or
not, the use of protective devices, and stopping trials
prematurely. However, these analyses were highly un-
derpowered and their results are likely unreliable. With-
in-trial subgroup analyses also failed to identify signifi-
cant treatment interactions based on the severity of
stenosis,3 patient gender,7,20 the presence of symp-
toms,7,21 or whether MI was associated with Q wave.21
Age seemed to interact with treatment effect in the
individual patient-pooled analysis,24 Carotid Revascular-
ization Endarterectomy vs Stenting Trial (CREST),7 and
to a lesser extent in SPACE,20 suggesting CAS is more
efficacious in the young (age 70).
The exclusion of the two older RCTs3,13 does not
change study conclusions; that is, increased risk of stroke,
decreased risk of MI with stenting, and an unclear effect on
mortality.When analysis is restricted to the twomost recent
trials7,8 with the better methodology and with techniques
and skills that arguably are more contemporary, we find
CAS to be associated with a significant increase in the risk of
any stroke (RR, 1.82; 95% CI, 1.35-2.45) and mortality
(RR, 2.53; 95%CI, 1.27-5.08), and a nonsignificant reduc-
tion of the risk of MI (RR, 0.39; 95% CI, 0.12-1.23).
Asymptomatic patients. Outcome data in asymp-
tomatic patients are sparse and imprecise. The number of
patients who were asymptomatic across all trials was 1513
(20%); however, these patients had a small number of
events. Only one trial exclusively enrolled asymptomatic
patients and there were no events in either study arm.16 In
a second trial by Yadav et al,21 the cumulative incidence of
the primary composite endpoint of death,MI, or stroke was
not statistically different between CAS and carotid endar-
Table II. Absolute risk difference per 1000 patients
Outcome RD (95% CI) Quality of evidence
Death 3.44 (-1.29, 11.44) Moderatea
MI 10.15 (-13.17, -5.16) High
Stroke 18.77 (1.96, 42.23) High
CAS, Carotid artery stenting; CEA, carotid artery endarterectomy; CI, co
percentage with endarterectomy as a reference.
Analysis assumed the median control event rate from patients undergoing ca
meta-analyses.
aQuality of evidence downgraded due to imprecision of meta-analytic estimterectomy (CEA). In asymptomatic patients enrolled in rREST,7 the rates of death, MI, and any stroke were (0%,
.2%, and 2.5% for CAS; and 0%, 2.2%, and 1.4% for CEA).
REST findings are consistent with our main findings in all
atients (ie, suggest a trend for increasedMI with CEA and
ncreased stroke with CAS); however, these data are also
ery sparse and inference is limited.
ISCUSSION
We conducted a systematic review and meta-analyses
omparing CAS and CEA. These analyses update the evi-
ence base by more than doubling the number of random-
zed patients. CAS is associated with increased risk of stroke
ut decreased risk of perioperative nonfatal MI. The effect
n mortality remains unclear. The meta-analytic estimates
eem to be reliable with no significant heterogeneity. Out-
ome data were derived mainly from symptomatic patients.
here may be an age-benefit interaction suggesting that
AS should be particularly avoided in patients over 70.
Trading benefits and harms requires presenting treat-
ent effects to patients in absolute terms. As demonstrated
n this report, stenting would lead to 19 more strokes and
0 fewer MIs per 1000 treated patients. Patients typically
eek both procedures to prevent stroke as their primary
ndication for revascularization. Furthermore, the esti-
ated average decrement in quality of life associated with
troke exceeds that of MI (a quality-of-life score of 0.52 for
ajor stroke, 0.68 for moderate stroke, and 0.87 for minor
troke; compared to a score of 0.88 for MI).25,26 However,
his comparison remains challenging because of the lack of
larity in the published trials about the clinical significance
nd consequences of the MI described in these trials (clin-
cally significant vs being demonstrated by electrocardio-
ram and enzymes only, associated with Q wave vs not).
oreover, it seems as if CAS was associated with an
ncrease in primarily nondisabling strokes. From a societal
erspective, Markovian analysis conducted using direct
edicare costs demonstrated that CAS produced less
uality-adjusted life-years (8.97 vs 9.64) and an incremen-
al cost of $17,700.27 These analyses may not apply to
atients at different ages or with different vascular anatomy.
n all, the available evidence continues to support the
revious iteration of the Society for Vascular Surgery guide-
ines on the management of carotid artery disease. These
uidelines recommended that patients in need of carotid
Interpretation
AS is associated with 3 more deaths (from 1 fewer to 11 more)
AS is associated with 10 fewer MI’s (from 13 fewer to 5 fewer)
AS is associated with 19 more strokes (from 2 more to 42 more)
ce interval; MI, myocardial infarction; RD, risk difference presented as a
endarterectomy in the included trials and relative risks from random effectsC
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stenting should be offered to patients who have high peri-
operative coronary risk or anatomic risk for endarterectomy
such as previous CEA with recurrent stenosis, prior ipsilat-
eral radiation therapy to neck with permanent skin changes,
previous ablative neck surgery (eg, radical neck dissection,
laryngectomy), common carotid artery stenosis below the
clavicle, contralateral vocal cord paralysis, or presence of a
tracheostomy stoma.6
The strengths of this review stem from the comprehen-
sive literature search that follows an explicit protocol and
bias protection measures undertaken by reviewers (such as
selecting studies, evaluating studies quality, and extracting
outcome data by two independent reviewers). The weak-
nesses stem from inability to evaluate patient-level covari-
ates that are needed to conduct meaningful subgroup anal-
yses. Such analyses may demonstrate differential benefit of
CAS or CEA in a particular gender, age, or other patient
groups. Another limitation is the paucity of data in asymp-
tomatic patients making inferences in this subgroup of
patients challenging. Compared with previous reviews,4,28
this report has more randomized patients and higher pre-
cision and includes RCTs with fewer methodological short-
comings; therefore, these results offer higher-quality evi-
dence, more precise results, and should yield stronger
inferences.
The robustness of the currently available data and its
relationship to the results of future and ongoing RCTs
can be appreciated by estimating the Optimal Informa-
tion Size.29 This concept is based on the assumption that
the sample size required for a reliable and conclusive
meta-analysis is at least as large as that of a single
optimally powered RCT. Using a desired power of 90%,
two-sided  value of 0.05, the control event rate and
relative risks observed in this meta-analysis, we find the
optimal information size (sample size needed) to be
4516 and 4177 patients for stroke and MI, respectively.
The current evidence base fulfills this assumption.
Hence, it seems that our inferences are robust unless the
stenting technique changes and the associated incidence
of stroke significantly declines. On the other hand, if one
considers the effect on major and disabling stroke (as
opposed to any stroke), or considers inferences in asymp-
tomatic patients, data remain sparse and definitive rec-
ommendations will be very sensitive to the results of
future trials. Lastly, there is a growing consensus that
future trials of carotid intervention in neurologically
asymptomatic patients will have to include a noninter-
vention arm that receives the best available medical
management. It is plausible that intensive medical treat-
ment may trump all interventions if all three outcomes
(MI, stroke, and death) were considered as primary
outcomes. A medical intervention arm would preserve
true equipoise.
The Society for Vascular Surgery is planning to update
their clinical practice guidelines on the management of
carotid artery disease. A panel of experts will use data from
this report and other sources of evidence and incorporate
1dditional relevant aspects such as patients’ values, prefer-
nces, resource allocation, and clinical context to develop
linical recommendations.
ONCLUSION
Compared with endarterectomy, CAS increases the risk
f any stroke and decreases the risk of MI. Outcome data in
symptomatic patients remain sparse and imprecise.
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